deprexis®24-NOW deprexis®24-new online cognitive behavioral therapy with or without pharmacotherapy

deprexis®24-NOW deprexis®24-new online cognitive behavioral therapy with or without pharmacotherapy - deprexis®24-NOW

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011628

Enrollment

1800

Registered

2017-01-26

Start date

2016-11-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32

Interventions

Group 1: Data of ambulatory patients with a depressive mood or depression who use deprexis®24 as an online psychotherapy program according to the current patient information should be documented over

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Ambulatory patients with a depressive mood or depression who use deprexis®24 as an online psychotherapy program according to the current patient information.

Exclusion criteria

Exclusion criteria: Patients under 18 years

Design outcomes

Primary

Measure	Time frame
Aim of this clinical study of a medical device according to §23b MPG is to examine the application and effectiveness of the online-based psychotherapy program deprexis®24 for the therapeutic support of adult patients with depressive mood or depression, with or without comedication. Data are collected under routine conditions over an observation period of 3 months. The following questions are to be analyzed: 1) Findings on the use of deprexis®24 in outpatient patients of daily practice a) Change of depressive symptoms during and after application (short version Montgomery Asberg Depression Scale (svMADRS), Clinical Global Impression-Severity/Improvement (CGI-S / CGI-I), Patient Health Questionnaire (PHQ-9); at all 4 visits (U1-U4)) b) Influence of the application on the social function of the patient (Sheehan Disability Scale (SDS); at all 4 visits (U1-U4)) 2) Findings on the treatment effect of deprexis®24 with / without comedication (standardized documentation; at all 4 visits (U1-U4)) 3) Findings about patient satisfaction with the application of deprexis®24 (Client Satisfaction Questionnaire (CSQ-4); U4) 4) Collection of compliance with the online psychotherapy program (standardized Questionnaire; U2-U4) 5) Obtaining insights into specific safety-related incidents under deprexis®24 and adverse events (UE) under a possible comedication (standardized Questionnaire; U2-U4).	—

Measure

Time frame

Aim of this clinical study of a medical device according to §23b MPG is to examine the application and effectiveness of the online-based psychotherapy program deprexis®24 for the therapeutic support of adult patients with depressive mood or depression, with or without comedication. Data are collected under routine conditions over an observation period of 3 months. The following questions are to be analyzed: 1) Findings on the use of deprexis®24 in outpatient patients of daily practice a) Change of depressive symptoms during and after application (short version Montgomery Asberg Depression Scale (svMADRS), Clinical Global Impression-Severity/Improvement (CGI-S / CGI-I), Patient Health Questionnaire (PHQ-9); at all 4 visits (U1-U4)) b) Influence of the application on the social function of the patient (Sheehan Disability Scale (SDS); at all 4 visits (U1-U4)) 2) Findings on the treatment effect of deprexis®24 with / without comedication (standardized documentation; at all 4 visits (U1-U4)) 3) Findings about patient satisfaction with the application of deprexis®24 (Client Satisfaction Questionnaire (CSQ-4); U4) 4) Collection of compliance with the online psychotherapy program (standardized Questionnaire; U2-U4) 5) Obtaining insights into specific safety-related incidents under deprexis®24 and adverse events (UE) under a possible comedication (standardized Questionnaire; U2-U4).

—

Countries

Germany

Contacts

Public ContactBettina Barthel

Servier Deutschland GmbH

bettina.barthel@servier.com089/57095-01

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026